Skip to main content

Advertisement

SpringerLink
Log in

Strategies for Managing Chemotherapy-Induced Sensory Neuropathy

  • Published:
Current Colorectal Cancer Reports

Abstract

Chemotherapy-induced sensory neuropathy occurs in most patients undergoing treatment with oxaliplatin for colorectal cancer. Although the acute form of neurotoxicity is transient, the chronic form, which is correlated with the cumulative dose of oxaliplatin administered over time, may be long lasting in a subset of patients and may have a significant impact on function and quality of life. Because treatment options for established chemotherapy-induced peripheral neuropathy are limited, recent efforts have focused on prevention. This review discusses acute and chronic neurotoxic effects of oxaliplatin, the most recent evidence for decreasing the probability of developing peripheral neuropathy, and the clinical management of existing neuropathy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance•• Of major importance

  1. Andre T, Boni C, Mounedji-Boudiaf L, et al.: Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004, 350:2343–2351.

    Article  CAS  PubMed  Google Scholar 

  2. Kuebler JP, Wieand HS, O’Connell MJ, et al.: Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol 2007, 25:2198–2204.

    Article  CAS  PubMed  Google Scholar 

  3. Haller D, Cassidy J, Tabernero J, et al.: Efficacy findings from a randomized phase III trial of capecitabine plus oxaliplatin versus bolus 5-FU/LV for stage III colon cancer (NO16968): No impact of age on disease-free survival (DFS) [abstract 284]. Presented at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium. Orlando, FL; January 22–24, 2010.

  4. •• Andre T, Boni C, Navarro M, et al.: Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 2009, 27:3109–3116. This article provides long-term follow-up data on the use of FOLFOX for adjuvant therapy. The percentages of patients with long-term peripheral neurotoxicity are given.

  5. Goldberg RM, Sargent DJ, Morton RF, et al.: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004, 22:23–30.

    Article  CAS  PubMed  Google Scholar 

  6. Raymond E, Chaney SG, Taamma A, Cvitkovic E: Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol 1998, 9:1053–1071.

    Article  CAS  PubMed  Google Scholar 

  7. Gamelin E, Gamelin L, Bossi L, Quasthoff S: Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures. Semin Oncol 2002, 29(5 Suppl 15):21–33.

    Article  CAS  PubMed  Google Scholar 

  8. Wilson RH, Lehky T, Thomas RR, et al.: Acute oxaliplatin-induced peripheral nerve hyperexcitability. J Clin Oncol 2002, 20:1767–1774.

    Article  CAS  PubMed  Google Scholar 

  9. Extra JM, Marty M, Brienza S, Misset JL: Pharmacokinetics and safety profile of oxaliplatin. Semin Oncol 1998, 25(2 Suppl 5):13–22.

    CAS  PubMed  Google Scholar 

  10. Lehky TJ, Leonard GD, Wilson RH, et al.: Oxaliplatin-induced neurotoxicity: acute hyperexcitability and chronic neuropathy. Muscle Nerve 2004, 29:387–392.

    Article  CAS  PubMed  Google Scholar 

  11. Verstappen CC, Heimans JJ, Hoekman K, Postma TJ: Neurotoxic complications of chemotherapy in patients with cancer: clinical signs and optimal management. Drugs 2003, 63:1549–1563.

    Article  CAS  PubMed  Google Scholar 

  12. • Land SR, Kopec JA, Cecchini RS, et al.: Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07. J Clin Oncol 2007, 25:2205–2211. This article specifically addresses neurotoxicity in patients enrolled in the oxaliplatin-based adjuvant trial C-07.

  13. de Gramont A, Figer A, Seymour M, et al.: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000, 18:2938–2947.

    PubMed  Google Scholar 

  14. Green E, Sargent DJ, Goldberg RM, Grothey A: Detailed analysis of oxaliplatin-associated neurotoxicity in Intergroup trial N9741 [abstract #182]. Presented at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium. Hollywood, FL; January 27–29, 2005.

  15. Grothey A: Clinical management of oxaliplatin-associated neurotoxicity. Clin Colorectal Cancer 2005, 5(Suppl 1):S38–S46.

    Article  CAS  PubMed  Google Scholar 

  16. Taieb S, Trillet-Lenoir V, Rambaud L, et al.: Lhermitte sign and urinary retention: atypical presentation of oxaliplatin neurotoxicity in four patients. Cancer 2002, 94:2434–2440.

    Article  CAS  PubMed  Google Scholar 

  17. Gornet JM, Savier E, Lokiec F, et al.: Exacerbation of oxaliplatin neurosensory toxicity following surgery. Ann Oncol 2002, 13:1315–1318.

    Article  PubMed  Google Scholar 

  18. • Windebank AJ, Grisold W: Chemotherapy-induced neuropathy. J Peripher Nerv Syst 2008, 13:27–46. This is a very comprehensive review of the mechanisms underlying chemotherapy-induced neuropathy and approaches to managing toxicity.

  19. Quasthoff S, Hartung HP: Chemotherapy-induced peripheral neuropathy. J Neurol 2002, 249:9–17.

    Article  CAS  PubMed  Google Scholar 

  20. Chaudhry V, Chaudhry M, Crawford TO, et al.: Toxic neuropathy in patients with pre-existing neuropathy. Neurology 2003, 60:337–340.

    Article  CAS  PubMed  Google Scholar 

  21. Grothey A, McLeod HL, Green EM, et al.: Glutathione S-transferase P1 I105V (GSTP1 I105V) polymorphism is associated with early onset of oxaliplatin-induced neurotoxicity [abstract 3509]. Presented at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium. Hollywood, FL; January 27–29, 2005.

  22. Tournigand C, Cervantes A, Figer A, et al.: OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer—a GERCOR study. J Clin Oncol 2006, 24:394–400.

    Article  CAS  PubMed  Google Scholar 

  23. Maindrault-Goebel F, Lledo G, Chibaudel B, et al.: Final results of OPTIMOX2, a large randomized phase II study of maintenance therapy of chemotherapy-free intervals (CFI) after FOLFOX in patients with metastatic colorectal cancer (MRC): a GERCOR study [abstract 4013]. Presented at the American Society of Clinical Oncology Annual Meeting. Chicago, IL; June 1–5, 2007.

  24. •• Grothey A, Hart L, Rowland K, et al.: Intermittent oxaliplatin administration improves time-to-treatment failure in metastatic colorectal cancer: final results of the phase III CONcePT trial [abstract 4010]. Presented at the American Society of Clinical Oncology Annual Meeting. Chicago, IL; May 30–June 2, 2008. This study showed that the intermittent oxaliplatin administration strategy can improve time to treatment failure with a trend toward improved PFS.

  25. ClinicalTrials.gov: A Study of Avastin (Bevacizumab) Plus Crossover Fluoropyrimidine-Based Chemotherapy in Patients With Metastatic Colorectal Cancer. Available at http://clinicaltrials.gov/ct2/show/NCT00700102?term=AIO0504&rank=1. Accessed February 12, 2010.

  26. ClinicalTrials.gov: Combination Chemotherapy and Bevacizumab With or Without Erlotinib in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed by Surgery. Available at http://clinicaltrials.gov/ct/show/NCT00265824?order=2. Accessed February 12, 2010.

  27. Argyriou AA, Chroni E, Koutras A, et al.: A randomized controlled trial evaluating the efficacy and safety of vitamin E supplementation for protection against cisplatin-induced peripheral neuropathy: final results. Support Care Cancer 2006, 14:1134–1140.

    Article  PubMed  Google Scholar 

  28. Pace A, Carpano S, Galiè E, et al.: Vitamin E in the neuroprotection of cisplatin induced peripheral neurotoxicity and ototoxicity [abstract 9114]. Presented at the American Society of Clinical Oncology Annual Meeting. Chicago, IL; June 1–5, 2007.

  29. Kottschade LA, Sloan JA, Mazurczak MA, et al.: The use of vitamin E for prevention of chemotherapy-induced peripheral neuropathy: a phase III double-blind, placebo controlled study—N05C3 [abstract 9532]. Presented at the American Society of Clinical Oncology Annual Meeting. Orlando, FL; May 29–June 2, 2009.

  30. Mitchell PL, Goldstein D, Michael M, et al.: Addition of gabapentin to a modified FOLFOX regimen does not reduce oxaliplatin-induced neurotoxicity. Clin Colorectal Cancer 2006, 6:146–151.

    Article  CAS  PubMed  Google Scholar 

  31. Cascinu S, Catalano V, Cordella L, et al.: Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2002, 20:3478–3483.

    Article  CAS  PubMed  Google Scholar 

  32. Cassidy J, Bjarnason GA, Hickish T, et al.: Randomized double blind (DB) placebo (Plcb) controlled phase III study assessing the efficacy of xaliproden (X) in reducing the cumulative peripheral sensory neuropathy (PSN) induced by the oxaliplatin (Ox) and 5-FU/LV combination (FOLFOX4) in first-line treatment of patients (pts) with metastatic colorectal cancer (MCRC) [abstract 3507]. Presented at the American Society of Clinical Oncology Annual Meeting. Atlanta, GA; June 2–6, 2006.

  33. Gamelin L, Boisdron-Celle M, Delva R, et al.: Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-Fluorouracil and leucovorin for advanced colorectal cancer. Clin Cancer Res 2004, 10:4055–4061.

    Article  CAS  PubMed  Google Scholar 

  34. • Nikcevich DA, Grothey A, Sloan JA, et al.: Effect of intravenous calcium and magnesium (IV CaMg) on oxaliplatin-induced sensory neurotoxicity (sNT) in adjuvant colon cancer: results of the phase III placebo-controlled, double-blind NCCTG trial N04C7 [abstract 4009]. Presented at the American Society of Clinical Oncology Annual Meeting. Chicago, IL; May 30–June 2, 2008. In this randomized trial, Ca/Mg infusions did not compromise the efficacy of oxaliplatin-based therapy in the adjuvant setting.

  35. Hammack JE, Michalak JC, Loprinzi CL, et al.: Phase III evaluation of nortriptyline for alleviation of symptoms of cis-platinum-induced peripheral neuropathy. Pain 2002, 98:195–203.

    Article  CAS  PubMed  Google Scholar 

  36. Kautio AL, Haanpaa M, Saarto T, Kalso E: Amitriptyline in the treatment of chemotherapy-induced neuropathic symptoms. J Pain Symptom Manage 2008, 35:31–39.

    Article  CAS  PubMed  Google Scholar 

  37. Rao RD, Michalak JC, Sloan JA, et al.: Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3). Cancer 2007, 110:2110–2118.

    Article  CAS  PubMed  Google Scholar 

  38. Rao RD, Flynn PJ, Sloan JA, et al.: Efficacy of lamotrigine in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled trial, N01C3. Cancer 2008, 112:2802–2808.

    Article  CAS  PubMed  Google Scholar 

  39. Barton DL, Wos E, Qin R, et al.: A randomized controlled trial evaluating a topical treatment for chemotherapy-induced neuropathy: NCCTG trial N06CA [abstract 9531]. Presented at the American Society of Clinical Oncology Annual Meeting. Orlando, FL; May 29–June 2, 2009.

Download references

Disclosure

Dr. Grothey has been a consultant to Amgen, Bayer, Pfizer, Roche/Genentech, Sanofi-Aventis, and Bristol-Myers Squibb. No other potential conflicts of interest relevant to this article were reported.

Author information

Authors and Affiliations

  1. Division of Medical Oncology, Mayo Clinic, 200 First Street Southwest, Rochester, MN, 55905, USA

    Joleen Hubbard & Axel Grothey

Authors
  1. Joleen Hubbard
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Axel Grothey
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Joleen Hubbard.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hubbard, J., Grothey, A. Strategies for Managing Chemotherapy-Induced Sensory Neuropathy. Curr Colorectal Cancer Rep 6, 126–132 (2010). https://doi.org/10.1007/s11888-010-0055-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11888-010-0055-0

Keywords

Search

Navigation